The following is a summary of “Effective and durable repigmentation for stable vitiligo: A randomized within-subject ...

Australian researchers have discovered a potential new lifeline for the tiniest and most vulnerable newborns. Scientists at ...

Humacyte stock has dropped 46% since July, mainly due to FDA review delays. Check out why I downgraded HUMA stock from "buy" ...

RECELL GO mini AVITA Medical receives FDA approval of RECELL GO mini, a new addition to the RECELL Spray-On Skin™ technology ...

Late-breaking research finds no survival benefit from autologous stem cell transplant in mantle cell lymphoma patients with ...

The director of solid tumor therapy at Stanford Medicine describes how cellular therapies are transforming cancer care.

The Global Autologous Cell Therapy Market has seen significant growth and is expected to continue expanding with a projected CAGR of 18.1% from 2019 to 2027, reaching a market value of approximately ...

Autologous stem cell transplant plus Rituxan did not improve survival outcomes in certain patients with mantle cell lymphoma compared with Rituxan alone.

Late-breaking research reveals there is no benefit from high-dose chemotherapy followed by autologous stem cell transplant ...

Benchmark analyst Bruce Jackson raised the firm’s price target on Humacyte (HUMA) to $17 from $15 and keeps a Buy rating on the shares.

To address these problems, we propose an autologous variable stiffness soft finger (AVSSF) that integrates the cross-layer jamming joints (CLJJs) as both the variable stiffness unit and the finger ...